Anticoagulation Guidelines for Patients with Impaired Renal Function

Introduction to DOAC Selection

• The American College of Cardiology recommends DOACs over warfarin for most patients with atrial fibrillation requiring anticoagulation, with apixaban being the preferred agent in moderate-to-severe renal impairment due to its lowest renal clearance (27%) 1, 2, 3

DOAC Selection Based on Renal Function

• For patients with severe renal impairment (CrCl 15-29 mL/min), apixaban 2.5 mg twice daily is the only DOAC with a dosing option in this range 4, 3
• Dabigatran 75 mg twice daily may be considered for CrCl 15-30 mL/min, though safety and effectiveness are not established 5
• Rivaroxaban 15 mg daily may be considered for CrCl 15-50 mL/min, but safety data are limited 5
• All DOACs are contraindicated when CrCl <15 mL/min or on dialysis 6, 4

DOAC Dosing in Moderate Renal Impairment

• Apixaban remains 5 mg twice daily unless patient meets dose reduction criteria (age ≥80 years, weight ≤60 kg, or creatinine ≥1.5 mg/dL—requires at least 2 of 3 criteria for reduction to 2.5 mg twice daily) 3
• Dabigatran should be reduced to 110 mg twice daily in moderate renal impairment (CrCl 30-49 mL/min) 6, 4
• Rivaroxaban should be reduced to 15 mg once daily in moderate renal impairment (CrCl 30-49 mL/min) 6, 4

Standard DOAC Dosing

• Standard DOAC dosing applies for all agents in patients with mild renal impairment (CrCl 50-80 mL/min), including dabigatran 150 mg twice daily, rivaroxaban 20 mg once daily, apixaban 5 mg twice daily, and edoxaban 60 mg once daily 1, 2

When to Use Warfarin Instead of DOACs

• The American College of Cardiology recommends warfarin over DOACs for patients with mechanical heart valves or moderate-to-severe mitral stenosis 1, 2
• Warfarin is also recommended for patients with CrCl <15 mL/min or dialysis-dependent patients 6, 4

Critical Monitoring Requirements

• Baseline renal function must be assessed before initiating any DOAC, with annual monitoring for patients with normal renal function and more frequent monitoring for patients with moderate renal impairment (CrCl 30-49 mL/min) 4, 3
• The HAS-BLED score should be used to identify modifiable bleeding risks, and dabigatran and rivaroxaban carry increased gastrointestinal bleeding risk compared to warfarin in patients ≥75 years 4, 6

Special Considerations in Renal Impairment

• The European Heart Journal recommends avoiding combining DOACs with P-gp inhibitors (ketoconazole, dronedarone, ritonavir) in patients with CrCl <50 mL/min 6
• Concomitant use of NSAIDs, antiplatelets, SSRIs, or SNRIs should be avoided when possible due to increased bleeding risk 6, 3

Age-Related Considerations

• Patients ≥75 years have higher bleeding risk with all anticoagulants, and apixaban dose reduction to 2.5 mg twice daily is mandatory when ≥2 criteria are met (age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL) 6, 3

Common Pitfalls to Avoid

• Failing to reassess renal function periodically leads to inappropriate dosing and increased bleeding risk 4, 3
• Combining anticoagulants with antiplatelets without clear indication is not recommended due to safety concerns 5